Abstract 3762: Second generation PIM inhibitors exhibit improved activity in solid tumor models
Jason M. Foulks(Astex Pharmaceuticals), Steven B. Kanner(Energy Biosciences Institute), Ashley Chan(Astex Pharmaceuticals), Benjamin Brenning(Astex Pharmaceuticals), Shannon Merx(Astex Pharmaceuticals), Anna V. Senina(Astex Pharmaceuticals), Marcus Wilkes(Astex Pharmaceuticals), David Vollmer(Astex Pharmaceuticals), Xiaohui Liu(Hebei Medical University), Jihua Liu(China Pharmaceutical University), Li‐Wen Huang(Fuda Cancer Hospital), Shuping Lai(Astex Pharmaceuticals), Yong Xu(Astex Pharmaceuticals), Michael Saunders(Astex Pharmaceuticals), Adrianne Clifford(Astex Pharmaceuticals), Michael V. McCullar(Astex Pharmaceuticals), Koc-Kan Ho(Astex Pharmaceuticals), Bai Luo(Central South University)
Cited by 1
Related Papers
Paracrine Action of Mesenchymal Stem Cells Revealed by Single Cell Gene Profiling in Infarcted Murine Hearts
|PLoS ONE|2015|93
Effects of fermentation duration on the flavour quality of large leaf black tea based on metabolomics
|Food Chemistry|2024|55